Glenmark Life IPO attractively priced
With a portfolio of 120 molecules, GLS is a leading developer of select high-value, non-commoditised APIs in chronic therapies. It earns one-third of its revenues from supplying APIs to its parent and the rest from regulated markets as GLS works with 16 of the 20 largest generic companies in the world.